Keywords: Vaccine, pertussis, bordetella, conjugates
Collaboration Research Opportunity: The National Institute of Child Health and Human Development (NICHD) is seeking statements of capability or interest from parties interested in collaborative research to further co-develop vaccines against pertussis.
Description of Technology: Despite mass vaccination, reported pertussis cases have increased in the United States and other parts of the world, probably because of increased awareness, improved diagnostic means, and waning vaccine-induced immunity among adolescents and adults. Licensed vaccines do not kill the organism directly; the addition of a component inducing bactericidal antibodies would improve vaccine efficacy. This application claims Bordetella pertussis and Bordetella bronchiseptica LPS-derived core oligosaccharide (OS) protein conjugates. B. pertussis and B. bronchiseptica core OS were bound to aminooxylated BSA via their terminal Kdo residues. The two conjugates induced similar anti-B. pertussis LPS IgG levels in mice. Conjugate-induced antisera were bactericidal against B. pertussis.
Potential Commercial Applications:
Research Status: Pre-clinical, in vivo data available.
References: Kubler-Kielb J, Vinogradov E, Lagergard T, Ginzberg A, King JD, Preston A, Maskell DJ, Pozsgay V, Keith JM, Robbins JB, Schneerson R., "Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine," Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4087-92. Epub 2011 Feb 22. PMID: 21367691.
Patent Status: US Application No. 61/438,190, filed 31 Jan 2011
Joseph Conrad, Ph.D., J.D.
Technology Transfer Specialist
Please reference abstract # E-006-2011
Last updated: 7/20/2011